ClinicalTrials.gg
CompletedNCT01692717Updated Oct 31, 2022

Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide

A Phase 1 interventional study of Atorvastatin and Hydrochlorothiazide + Losartan in Healthy Subjects, sponsored by Azidus Brasil. Completed at 1 site in Brazil. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-31.

Sponsored by Azidus Brasil · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of this clinical study, randomized, crossover is to evaluate the pharmacokinetic profile of the polypill (atorvastatin + lorsatana + hydrochlorothiazide) Laboratory Hypermarcas S / A, in relation to drugs Citalor ® (atovastatina - Pfizer) and Hyzaar ® (losartan + hydrochlorothiazide - Merck Sharp \& Dohme) by comparing the serum concentration of analytes unchanged (AT, LS and HCTZ) in healthy subjects.

Read the detailed description

The pharmacokinetic profile of the drug will also be assessed by comparing the serum concentration of active metabolites following:

  • O-hydroxy atorvastatin (2-Hydroxy atorvastatin, O-HAT): metabolite of AT
  • carboxylic acid (E-3174, LS-CA): active metabolite of LS
02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Azidus Brasil is the lead sponsor of 80 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirm voluntary participation and agree to all the purposes of the study by signing and dating the IC in two ways;
  2. Age between 18 and 55 years, regardless of sex, clinically healthy and present laboratory parameters within normal limits;
  3. ≥ 18.5 and ≤ 30.

Exclusion criteria

Exclusion Criteria:

  1. Participation in clinical trials in the 12 months preceding the survey;
  2. History of reactions to atorvastatin, losartan hydrochlorothiazide and / or any other ingredients of medicines;
  3. Alterations in clinical and laboratory criteria that interfere Principal Investigator on the study results;
  4. Presence of pulmonary diseases, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems;
  5. Acute illness during the 07 days preceding the start of the study;
  6. Chronic disease that determine drug delivery, such as hypertension, diabetes or any other that requires continuous use of any medicine, including use of vitamins, mineral supplements and OTCs (over-the-counter);
  7. Having made regular use of medication in the last 02 weeks before the onset of the study. The use of any medication that does not interfere with the physician's judgment on the pharmacokinetics of the drug under study, will not be considered as an exclusion criterion.
  8. Use of medications that interact with any medications association;
  9. History of or current use for at least 12 months of tobacco;
  10. Current or previous history (under 12 months) of illicit drug use;
  11. At the discretion of the Principal Investigator of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    Atorvastatin

    Citalor (Atorvastatin) - Pfizer

    Drug: Atorvastatin · Drug: Hydrochlorothiazide + Losartan · Drug: Hydrochlorothiazide + Losartan + Atorvastatin

  • Active comparator
    Hydrochlorothiazide + Losartan

    Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp \& Dohme

    Drug: Atorvastatin · Drug: Hydrochlorothiazide + Losartan · Drug: Hydrochlorothiazide + Losartan + Atorvastatin

  • Experimental
    Atorvastatin + Hydrochlorothiazide + Losartan

    Polipílula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas

    Drug: Atorvastatin · Drug: Hydrochlorothiazide + Losartan · Drug: Hydrochlorothiazide + Losartan + Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. The primary pharmacokinetic parameters for the exercise of comparability will be unchanged dosages of analytes (AT, LS and HCTZ), assessed by AUC, Tmax, Cmax and T1 / 2.

    Time frame: 0h00, 0h15, 0h30, 0h45, 1h00, 1h15, 1h30, 1h45, 2h00, 2h30, 3h00, 3h30, 4h00, 4h30, 5h00, 6h00, 8h00, 10h00, 12h00, 18h00, 24h00, 36h00, 48h00, 56h00 e 72h00.

Secondary outcomes

  1. Pharmacokinetic parameters are side dosages of active metabolites O-HAT and E-3174, measured by AUC, Tmax, Cmax and T1 / 2.

    Time frame: 0h00, 0h15, 0h30, 0h45, 1h00, 1h15, 1h30, 1h45, 2h00, 2h30, 3h00, 3h30, 4h00, 4h30, 5h00, 6h00, 8h00, 10h00, 12h00, 18h00, 24h00, 36h00, 48h00, 56h00 e 72h00.

07

Study locations

1 site
  • LAL Clínica Pesquisa e Desenvolvimento Ltda
    Valinhos, São Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2013 to primary completion in May 2013, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2012
First posted
Sep 25, 2012
StartActual
Feb 28, 2013
Primary completionActual
May 31, 2013
CompletionActual
May 31, 2013
Last update
Oct 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01692717
Lead sponsor
Azidus Brasil
Responsible party
Sponsor
First posted
Sep 25, 2012
Start date
Feb 28, 2013
Primary completion
May 31, 2013
Completion
May 31, 2013
Last update
Oct 31, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Hydrochlorothiazide · Losartan

Start the discussion